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The management of moderate-to-severe psoriasis has been transformed by the
introduction of biological therapies. These medicines, particularly those targeting
interleukin (IL)-17 and IL-23p19, can offer clear or nearly clear skin for the
majority of patients with psoriasis, with good long-term drug survival. However,
as currently used, none of these therapies is curative and disconcertingly there is
a small but increasing number of patients with severe psoriasis who have failed
all currently available therapeutic modalities. A similar scenario has occurred in
other immune-mediated inflammatory diseases (IMIDs) where treatment options
are limited in severely affected patients. In these cases, cell therapy, including
haematopoietic stem cell transplantation (HSCT) and mesenchymal stromal cells
(MSC), has been utilized. This review discusses the various forms of cell therapy
currently available, their utility in the management of IMIDs and emerging evi-
dence for efficacy in severe psoriasis that is unresponsive to biological therapy.
Balancing the risks and benefits of treatment vs. the underlying disease is key;
cell therapy carries significant risks, costs, regulation and other complexities,
which must be justified by outcomes. Although HSCT has anecdotally been
reported to benefit severe psoriasis, sometimes with apparent cure, this has
mainly been in the setting of other coincidental ‘routine’ indications. In psoriasis,
cell therapies, such as MSC and regulatory T cells, with a lower risk of complica-
tions are likely to be more appropriate. Well-designed controlled trials coupled
with mechanistic studies are warranted if advanced cell therapies are to be devel-
oped and delivered as a realistic option for severe psoriasis.
Introduction
Psoriasis is a common, immune-mediated inflammatory dis-
ease (IMID) with significant morbidity and detrimental impact
on the affected individual’s quality of life. It is associated with
important medical conditions, including psoriatic arthritis
(PsA), metabolic syndrome, depression and cardiovascular dis-
ease; people with psoriasis have a higher mortality than the
general population.1 The complex interplay between genetic,
epigenetic, immune and environmental factors that underlie
the disease pathogenesis is not fully understood.2 However,
the emergence of biological therapies targeting key immune
pathways in psoriasis pathogenesis, such as tumour necrosis
factor (TNF)-a, interleukin (IL)-17 and IL-23, has
revolutionized the treatment landscape of severe disease. These
therapies can lead to significant improvement in disease bur-
den and quality of life for people with psoriasis. However,
targeted therapies are not curative; their limitations include
lack of clinical response in certain individuals, diminishing
efficacy over time and occasional significant adverse effects.3
Consequently, there is an increasing number of patients with
psoriasis who are refractory to multiple lines of biological and
nonbiological systemic therapies. This underscores an urgent
and increasing need for more advanced, perhaps curative,
treatment options including nonpharmaceutical approaches for
severe psoriasis.
Cell therapy comprises the use of somatic cells (stem, pro-
genitor or primary cells) isolated from either the affected
© 2021 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists
British Journal of Dermatology (2021) 1
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
individual (autologous) or a donor (allogeneic) to treat the
underlying disease. The various types of somatic cells that are
used, or have the potential to be used, as cell therapy in IMIDs
include haematopoietic stem cells (HSCs), mesenchymal stem
or stromal cells (MSCs), multilineage-differentiating stress-
enduring (Muse) cells, fibroblasts, induced pluripotent stem
cells (iPSCs), regulatory T cells (Tregs) and chimeric antigen
receptor (CAR)-T cells. The last two decades have witnessed
rapid advances in clinical trials and commercialization of cell
therapy, for which the three most common disease indications
in Europe between 2004 and 2014 were cancer, cardiovascu-
lar disease and connective tissue diseases.4 Observations of
serendipitous ‘transfer’ and ‘cure’ of IMIDs after HSC trans-
plantation (HSCT) have raised interest in the potential of cell
therapy as an option for these conditions with a number of
controlled and open studies mainly in multiple sclerosis (MS),
musculoskeletal disease and systemic sclerosis (SS). Similar
observations of ‘transfer’ and ‘cure’ have been made for psori-
asis over the years, but there are few subsequent hypothesis-
testing studies. Thus, there appears to be a rationale and an
impetus to explore the use of cell therapy in psoriasis, specifi-
cally for patients who are refractory to currently available
therapies.
This review discusses the following three key aspects of cell
therapy: (i) types of cell therapy for IMIDs; (ii) accumulated
data on the use of cell therapy in the management of psoria-
sis; and (iii) the future direction of cell therapy for psoriasis.
Types of cell therapy
The various types of cell therapy that have been used, or have
the potential to be used, in IMIDs are detailed in Figure 1.
Types of cell therapy used for immune-mediated
inflammatory diseases
Haematopoietic stem cell transplantation
HSCT is used to treat a wide range of malignant and nonma-
lignant conditions.5 It involves intravenous infusion of allo-
geneic or autologous HSCs following myeloablative and/or
lymphoablative cytotoxic therapy. The preparative ‘condition-
ing’ regimen may include various combinations of high-dose
chemotherapy, total body irradiation and ‘serotherapy’, such
as polyclonal antithymocyte globulin, or therapeutic mono-
clonal antibodies, e.g. alemtuzumab or rituximab. Sources of
HSCs include granulocyte colony-stimulating factor-mobilized
peripheral blood stem cells, bone marrow and umbilical cord
blood.6 Allogeneic HSCT requires ongoing immunosuppres-
sion, usually ciclosporin or tacrolimus, to facilitate engraft-
ment and prevent graft-versus-host disease (GVHD), until
tolerization occurs thereby enabling withdrawal. The overall
aim of HSCT is to remove the underlying disease process and
reconstitute the blood and immune systems, which in allo-
geneic HSCT may be accompanied by a graft-versus-tumour
reaction.
Over the last quarter century, autologous HSCT has been
increasingly used to treat individuals with IMIDs, including
MS, SS and other rheumatological diseases and Crohn disease
where, despite modern treatments, some patients have ongo-
ing poor disease control and potentially shortened life expec-
tancy. In these ‘difficult-to-treat’ patients, HSCT has been
explored as an intensive means of disease control, delivered as
a ‘one-off’ treatment with long-term effectiveness. In some
IMIDs, such as severe relapsing-remitting MS and SS, random-
ized controlled trials (RCTs) support sustained benefits of
HSCT, whereas in other IMIDs, there appears to be a resetting
of disease activity to controllable levels.
In highly active resistant relapsing-remitting MS, there has
been a single phase III RCT comparing autologous HSCT with
various standard-of-care disease-modifying therapies (DMTs).7
Among 110 patients randomized on a 1 : 1 basis, only three
patients had disease progression at 1 year as primary endpoint
vs. 34 patients in the DMT group. There was also significant
improvement of MS at one year and beyond without
treatment-related mortality (TRM).7
In severe SS, there has been one small phase I RCT8 and
two phase III RCTs, namely ‘SCOT’9 and ‘ASTIS’,10 each using
different transplant regimens but with similar control arms. In
the North American ‘SCOT’ trial, Kaplan–Meier estimates at
72 months of event-free survival were 74% vs. 47%, and for
overall survival were 86% vs. 51%, for HSCT and control,
respectively.9 The TRM was 3% at 54 months and 6% at
72 months.9 These results confirmed similar findings from the
earlier European ‘ASTIS’ trial, which also showed significant
improvements in event-free and overall survival, with a TRM
of 10%.10
These phase III trial results in MS and SS support the poten-
tially powerful and prolonged effect of autologous HSCT on
disease activity in severely affected patients with IMIDs, but
also highlight the importance of careful patient selection.
Underlying vital organ compromise from the IMID itself man-
ifests in the contrasting TRM between different diseases and
requires careful per patient justification of the procedure.
Allogeneic HSCT has been applied to IMIDs more rarely
because of the higher complication rate (including GVHD) but
long-term responses, and probably cures, have been achieved
across a variety of diseases.11–14 Although autologous and allo-
geneic HSCT have been anecdotally reported to benefit severe
psoriasis, sometimes with apparent cure, this has mainly been
in the setting of other coincidental ‘routine’ indications
(Table 1). Very rare cases involving patients treated specifically
for severe PsA have been reported to the European Society for
Blood and Marrow Transplantation Registry.14
Mesenchymal stromal cells
MSCs comprise a heterogeneous population of self-renewable,
multipotent non-HSCs with immunomodulatory, angiogenic,
anti-inflammatory and antiapoptotic properties.15,16 These
properties, combined with ease of isolation from human tis-
sues and ability to evade allogeneic rejection (owing to lack of
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expression of major histocompatibility complex [MHC] class II
and costimulatory molecules CD80 and CD86, and low levels
of MHC class I),17,18 make MSCs an ideal cell therapy for vari-
ous conditions, including IMIDs, without the need for cyto-
toxic conditioning regimes.19
MSCs are found in virtually all organs but are predomi-
nantly harvested from bone marrow (BM-MSCs), umbilical
cord (UC-MSCs), placental tissues, Wharton’s jelly, peripheral
blood, dental pulp, skin and adipose tissue (ADSCs). Depend-
ing on the source of MSCs, their biological characteristics can
vary, including differentiation capacity, paracrine potential and
immunomodulatory properties. For instance, BM-MSCs and
ADSCs express stemness markers Sox2 and Oct4 in vitro, which
enable them to maintain their differentiation capacity in the
long term,20 whereas ADSCs, when compared with BM-MSCs
and UC-MSCs, exhibit a stronger inhibitory effect on
peripheral blood B cells, T cells and natural killer (NK) cells
in vitro;21 but all three types can promote Treg and T helper
(Th)1 polarization, evidenced by the increased expression of
forkhead box (FOX)P3 and T-bet mRNA within purified acti-
vated T cells, and a reduction in TNF-a and perforin produc-
tion by activated NK cells.21
In terms of immunomodulation, MSCs participate in both
innate and adaptive immunity; their immune regulatory func-
tions are exerted via interactions with immune cells through
cell-to-cell contact and paracrine activity involving T cells, B
cells, NK cells, macrophages, monocytes, dendritic cells and
neutrophils (reviewed in Gao et al.22 and Song et al.).23 The
MSC secretome, encapsulated in extracellular vesicles, includes
several cytokines, growth factors and chemokines, including
transforming growth factor (TGF)-b1, TNF-a, prostaglandin-



































Figure 1 Types of cell therapy used, or with the potential to be used, in psoriasis. Cell therapy can be either allogeneic (cells from donor to
patient) or autologous (the patient’s own cells). Different types of somatic cells can be obtained from various tissues, isolated and expanded in
laboratories that meet Good Manufacturing Practice standards, and systemically administered to the patient at time of treatment. Fibroblasts and
Muse cells are isolated from dermis, whereas MSC can easily be isolated from adipose tissue or bone marrow. CAR-T; chimeric antigen receptor T;
iPSC, induced pluripotent stem cell; MSC, mesenchymal stromal or stem cell; Muse, multilineage-differentiating stress-enduring cells; Treg,
regulatory T cell.
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indoleamine-pyrrole 2,3-dioxygenase and nitric oxide, among
others.24,25
One of the translational challenges with MSCs is their scala-
bility. In this regard, ADSCs are often preferred as they can be
obtained in large quantities from liposuction,26,27 with better
proliferative capacity, higher yield, slower rate of senescence
and better preservation of a normal diploid karyotype than
BM-MSCs.28–31
To date, safety and efficacy of MSCs have been demon-
strated in early phase trials in IMIDs, including rheumatoid
arthritis, systemic lupus erythematosus (SLE), lupus nephritis,
SS, GVHD, MS, type I diabetes mellitus, autoimmune hepatitis
and inflammatory bowel disease (IBD).32–39 Specifically, a
meta-analysis of 477 patients with Crohn disease fistulae
showed a significantly increased healing rate and a lower
recurrence rate in those with severe disease receiving allo-
geneic ADSCs compared with those who received dose-
adjusted BM-MSCs, with an optimal cell dose of 2–4 9 107
cells mL1, indicating the considerable potential of MSCs for
the treatment of IBD.40 A recent phase II RCT of autologous
MSCs in 48 patients with MS demonstrated disease remission,
without safety issues, in 586% compared with 97% in a
sham-treatment group.39 However, most of the MSC-based tri-
als for IMIDs are still in early phase I or II clinical trials with
some promising results and no toxicity to date, but larger
controlled trials are needed to confirm their efficacy and long-
term safety.31,32,34,35,38,39 However, several MSC products
have been approved including Prochymal (Osiris Therapeutics,
Columbia, MD, USA) for acute GVHD in Canada and New
Zealand.22 One of the theoretical pitfalls of MSCs is risk of
carcinogenesis.17,41,42 Despite emerging knowledge and expe-
rience with clinical application of MSCs, the cell dose and fre-
quency of administration vary between trials and the optimal
dosing regimen has yet to be determined.
Regulatory T cells
Tregs regulate or suppress other immunocytes by controlling
response to self-antigens and nonself antigens, thus helping to
prevent autoimmunity and limit chronic inflammation. They
exert these functions through inhibitory cytokines (e.g. IL-
10), cytolysis (via granzyme A/B and perforin), metabolic dis-
ruption and modulation of dendritic cell maturation or func-
tion, and lymphocyte-activation gene-3 binding to MHC class
II molecules.43
Rapid progress in the clinical translation of adoptive cell
therapy of Tregs is underpinned by various preclinical models
of autoimmune diseases demonstrating the therapeutic poten-
tial of a unique FOXP3+ immunosuppressive subset of Tregs.
To date, there are more than 50 active and completed clinical
trials testing the safety and efficacy of Tregs for IMIDs includ-
ing pemphigus vulgaris, SLE, IBD, autoimmune hepatitis and
asthma.44,45 Published results indicate excellent safety profiles
and some efficacy in patients treated with as many as 25 bil-
lion Tregs. Although psoriasis is believed to represent an
imbalance between Th17 cells and Tregs, there are no studies
to ascertain whether Treg-based therapy can restore this bal-
ance.46 However, there are current challenges with the use of
Treg therapy for IMIDs, which include the variability in
expansion of Tregs ex vivo, the relative paucity of clinical grade
reagents required for the manufacture of Tregs for therapy
and the observation that tissue antigen-specific Tregs, although
more potent than polyclonal Tregs, are expressed in very low
numbers and are unstable. It may be that the opportunities
offered by synthetic biology, e.g. for CAR-T therapy, could be
harnessed for Treg therapy.44 Further investigation of the most
suitable Treg subset to use for a particular disease, and con-
trolled trials with larger sample size and a standardized dosing
regimen, are required to obtain robust evidence of the clinical
benefit of correcting breaks in immune tolerance in IMIDs.47
For further review of this topic please see Roth-Walter et al.48
Types of cell therapy with potential for use in immune-
mediated inflammatory diseases
There are a number of other forms of cell therapy that could
potentially be used in the treatment of psoriasis, although
these are not currently being tested in IMIDs. These include
fibroblasts, Muse cells, iPSCs and CAR-T cells.
Fibroblasts
Fibroblasts, which exhibit similar characteristics to MSCs with
immunomodulatory and regenerative properties through para-
crine effects, play a vital role in wound healing through depo-
sition of extracellular matrix and formation of scar tissue.49–53
Thus, fibroblasts can be considered as an alternative to MSCs
for immunomodulatory cell therapy.51 Both allogeneic and
autologous fibroblasts have been used for treatment of chronic
wounds including venous leg ulcers and recessive dystrophic
epidermolysis bullosa, with notable anti-inflammatory
effect.54–57 The main concern with fibroblast cell therapy is
the risk of fibrosis and hypertrophic scars.50 However, fibrob-
lasts from the papillary dermis have a particular therapeutic
relevance as they are involved in wound healing with anti-
inflammatory effects without fibrosis.58 Although fibroblasts
have not been tested in humans with IMIDs, their therapeutic
potential has been highlighted through a number of preclini-
cal studies using mouse models of IMIDs including type I dia-
betes, autoimmune arthritis, alopecia areata and MS.51,59–61
Multilineage-differentiating stress-enduring cells
Muse cells are pluripotent stem cells, occurring naturally in
tissues of mesenchymal origin, with regenerative, anti-
inflammatory, antiapoptotic, antifibrotic and immunomodula-
tory properties.62–64 They comprise 1–2% of BM-MSCs, 5% of
dermal fibroblasts and a small population in adipose tissue.65
Upon tissue injury, the alerting signal, sphingosine-1-
phosphate, induces mobilization of Muse cells to peripheral
blood, and subsequently to the site of damage.64 This is fol-
lowed by spontaneous differentiation into, and replenishment
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of, tissue-compatible cells for repair.64,66 Furthermore, Muse
cells have immunomodulatory properties, exerted via TGF-b1
and regulation of macrophages towards the M2-phenotype,
which make them an attractive therapeutic option for psoria-
sis.67,68 To date, Muse cells have been used clinically in the
context of an early phase trial in myocardial infarction,
demonstrating safety and efficacy.69
Inducible pluripotent stem cells
One of the main limitations of somatic cell-based therapy is
that the limited lifespan of differentiated cells after clinical
application inevitably leads to a decline in therapeutic efficacy
over time. One revolutionary technology provides a solution
to this issue – iPSCs can be produced from any somatic cell
(e.g. fibroblasts) using reprogramming factors (Oct-4, Sox-2,
Klf-4 and c-Myc) and can differentiate into specialized cell
types with indefinite expansion, thus resembling embryonic
stem cells.70–72 The fundamental concept in the use of iPSCs
as cell therapy is that they are differentiated into the desired
cell types, such as keratinocytes or Tregs, and then trans-
planted as tissue constructs or cell suspensions. Owing to their
unlimited self-renewal and differentiation potential, patient-
specific iPSCs can be genetically corrected and differentiated
into required somatic cell lineages and administered as an
autograft.72,73 Viral-mediated gene supplementation or gen-
ome editing using tools such as CRISPR/Cas9 can be applied
to iPSCs in their undifferentiated state to correct the underly-
ing molecular pathology. Although combined genome editing
and iPSC technology is used as cell therapy in various disease
models, clinical translation to humans is still limited to a nar-
row scope of indications. These comprise cardiovascular dis-
eases, neurological disorders, GVHD and ophthalmic diseases
such as age-related macular degeneration.74 Caution is needed
because if undifferentiated proliferating iPSCs are directly
administered, they can form malignant teratomas owing to
their highly proliferative nature and broad differentiation
potential.75 However, iPSCs hold huge promise as both a
regenerative and an immunomodulatory cell therapy for vari-
ous skin diseases.76
Chimeric antigen receptor-T cell therapy
CAR-T cells are derived by transferring genetically engineered
CAR fusion proteins via lentiviral or retroviral vectors into
autologous T cells. The CAR constructs usually comprise a
single-chain variable fragment antigen-recognition domain, a
transmembrane CD-3-derived T-cell activation domain and an
intracellular costimulatory domain, e.g. CD28. The CAR-T cells
recognize and kill antigen-bearing cells via cytokine release.
Before infusion, the recipient requires cytotoxic conditioning
therapy. CAR-T cell therapy has been used in the management
of haematological malignancies, especially B-cell lymphoma,
acute lymphoblastic leukaemia and myeloma,77 and is being
considered in the management of melanoma resistant to
checkpoint inhibitors.78 However, it carries a significant risk
of cytokine release syndrome and neurotoxicity in the short
term, and long-term immunodeficiency owing to depletion of
immune effectors.79
As they have the ability to achieve profound depletion of B
cells or other immune targets, genetically engineered T cells
have been considered in the context of IMIDs. In a recent pre-
clinical study to treat pemphigus vulgaris in a mouse model
of the disease, the results demonstrated selective reduction of
serum anti-Desmoglein (Dsg)3 antibody titres and improve-
ment in blistering, hair loss and histological acantholysis.80
These preclinical data have led to an early phase open-label
clinical trial of Dsg3-CAR-T therapy for patients with pemphi-
gus vulgaris (NCT04422912).80
Beneficial effects of cell therapy for psoriasis
Serendipity played an important role in determining our cur-
rent consideration of cell therapy as a viable option for
patients with refractory psoriasis. Eedy et al.81 reported on the
‘cure’ of severe intractable psoriasis in a 35-year-old man who
received an allogeneic HSCT from his unaffected brother for
acute myelomonocytic leukaemia. The recipient remained free
of psoriasis 5 years post-transplant. Although the mechanisms
underlying the efficacy of allogeneic HSCT in psoriasis remain
elusive, it is postulated that the immunosuppressive drugs and
immunoablation needed for the procedure deplete autoreactive
T cells while the transplant reconstitutes the immune system
with potentially nonreactive T-cell populations from a donor
without psoriasis. This postulation is supported by reports that
long-term (up to 20 years) complete resolution of psoriasis
has been described in patients who received allogeneic, rather
than autologous, HSCT.82–84 Interestingly, the presence of
GVHD seemed to be an indicator for long-term complete
remission of psoriasis in eight cases (Table 1),82–105 possibly
owing to a ‘graft-versus-autoimmunity’ effect with ongoing
inhibition or elimination of the host immunohaematopoietic
system.84,91 Indeed, many of the participants listed in Table 1
received immunosuppressive conditioning regimens and con-
comitant therapies, including methotrexate and ciclosporin,
which are key confounders to the therapeutic benefit of HSCT.
The opposite, i.e. ‘transfer’ of psoriasis, was reported by
Snowden and Heaton106 in a 40-year-old man with acute
myeloid leukaemia who received a syngeneic HSCT from his
phenotypically identical twin brother who had been affected
by severe psoriasis and PsA for 20 years. Within 10 days of
transplantation, the recipient developed psoriasis which
remained intractable. Psoriasis persisted, despite receiving a
second transplant from the same donor, in addition to the
development of PsA. This case indicates that cellular aspects of
psoriasis may be transmitted by adoptive transfer.
Conversely, autologous HSCT does not appear to be curative
for psoriasis; relapses are frequent and may occur more than
10 years after transplantation. To date, of the 11 patients with
psoriasis treated with autologous HSCT, five relapsed within
2 years after the transplantation and one relapsed after
13 years (Table 1).100 Notably, even though psoriasis relapses,
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it appears to run a more benign, less clinically severe course
compared with the pretransplant state. Psoriasis remission after
autologous HSCT is attributed to the myelo- and lymphoabla-
tive effect of conditioning regimens and altered and slow
immunological reconstitution following transplantation.98
HSCT carries significant risks, costs and other complexities,
which must be justified by outcomes compared with alterna-
tive treatments. Risks are greater with allogeneic HSCT than
with autologous HSCT. In practice, individualized decisions
need to be made for each patient with respect to treatment
options for their disease. Severe intractable psoriasis is fre-
quently physically and psychologically debilitating and stan-
dard and novel treatments are not without side-effects.
However, the risk–benefit balance of allogeneic HSCT would
rarely be justified, even with the apparent potential for cure
(Table 1). Autologous HSCT has lower risks, which have been
acceptable in some IMIDs (such as MS and SS), but the out-
comes of ‘serendipitous’ treatment where psoriasis has coex-
isted with a standard indication for HSCT are, at best,
generally only supportive of temporary disease control.
Thus, MSC therapy may be a more attractive, more risk-
averse approach to cell therapy for psoriasis (Table 1). De
Jesus104 reported on two patients with intractable psoriasis,
one of whom had concomitant PsA, who received autologous
MSCs in the form of two to three infusions of liposuction-
derived ADSCs. A durable response with clinical benefit in the
form of a 50–60% reduction in Psoriasis Area and Severity
Index lasting between 157 and 292 days occurred, although
PsA was unresponsive. There were no concerning safety sig-
nals. Furthermore, even though there was an eventual relapse
of psoriasis, one patient responded to etanercept – a biologic
that had previously been ineffective for him – after MSC ther-
apy, thereby indicating that MSCs could be used as adjunctive
therapy. Chen et al.103 commented on two cases. The first case
was a 35-year-old man with diffuse large B-cell lymphoma
(DLBCL) and concomitant psoriasis who was treated with
autologous HSCT on two occasions; psoriasis improved briefly
both times after the conditioning regimen before relapsing.
The transplants were unsuccessful in controlling the DLBCL.
The patient then received one infusion of UC-MSCs as adjunc-
tive therapy. Both lymphoma and psoriasis remitted and
remained in remittance for at least 5 years. The second case
involved a 26-year-old woman who had intractable psoriasis
for 18 years. Three infusions of UC-MSCs were given specifi-
cally for the treatment of psoriasis, which produced clearance
that was maintained for at least 4 years with two further infu-
sions. UC-MSCs appear to be safe and seem to have remittive
potential in these cases. Chen et al.107 explored the mechanism
of action of UC-MSCs for psoriasis using the imiquimod
mouse model and infusion of human UC-MSCs which signifi-
cantly reduced psoriasis severity. A key feature of the response
was reduced production of type I interferon by plasmacytoid
dendritic cells. Wang et al.105 used five infusions of allogeneic
gingival MSCs, which have immunomodulatory and anti-
inflammatory properties, to treat a 19-year-old man who had
severe plaque psoriasis refractory to systemic therapy.
Clearance of psoriasis occurred after the fifth infusion and the
patient remained clear of psoriasis three years later.
These encouraging observations of the effectiveness and rel-
ative safety of MSCs in the treatment of psoriasis have led to
seven current phase I–II clinical trials (six in China and one in
South Korea; three using ADSCs and four using UC-MSCs, all
allogeneic) (Table 2).
Conclusions and future directions
As the number of people with psoriasis refractory to current
biological and nonbiological systemic therapies continues to
rise, and the pipeline for new pharmacological approaches to
the disease starts to shrink, it is important to turn to novel
holistic approaches and advanced therapeutics for a cure. Amid
all the interest in advanced therapeutics, it should be noted
that cell therapy is not necessarily the only option available
for the management, although perhaps not cure, of severe
psoriasis. Stratified medicine offering a targeted proactive
approach to the management of psoriasis, coupled with life-
style modification and ideally early temporal intervention in
the disease pathway, could also offer long-term remission.
Of the three therapeutic strategies for IMIDs, namely small
molecules, biologics and advanced cell therapy, only the latter
offers the potential to fulfil the remit of a cure. However, in
psoriasis there are important issues relating to risk–benefit bal-
ance, costs and complexity of treatment, including significant
regulatory issues where ‘cells’ are considered along similar
pathways to drugs. Cell therapy in the form of MSCs may
offer an attractive and safer option in psoriasis. At the same
time, other forms of cell therapy such as Tregs, fibroblasts,
Muse cells and iPSCs should be considered as alternative devel-
opmental approaches. Any decision to use cell therapy in the
management of psoriasis must be a joint one, made with close
collaboration between transplant haematologists and/or other
experts in cell therapy and clinicians experienced in the man-
agement of severe psoriasis. Beyond individual compassionate
use of MSCs, there is a pressing need for controlled trials of
their use in the management of refractory psoriasis, ideally
coupled with mechanistic studies to define mode of action.
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